Table 1.
Clinical characteristics of the study cohort.
| All (n = 341) |
|
|---|---|
| Clinical characteristics | |
| Age in years (mean, SD) | 61 (16) |
| <45, n (%) | 52 (15.2%) |
| 45–64, n (%) | 150 (44.0%) |
| 65–79, n (%) | 95 (27.9%) |
| ≥80, n (%) | 44 (12.9%) |
| Male, n (%) | 211 (61.9%) |
| White race, n (%) | 224 (65.7%) |
| Black race, n (%) | 92 (27.0%) |
| BMI kg/m2, mean (SD) | 30.79 (7.58) |
| Current or former smoker, n (%) | 112 (32.8%) |
| Diabetes mellitus, n (%) | 116 (34.0%) |
| Hypertension, n (%) | 206 (60.4%) |
| Coronary artery disease, n (%) | 47 (13.8%) |
| Congestive heart failure, n (%) | 47 (13.8) |
| Laboratory parameters | |
| Admission eGFR, mL/min/1.73 m2, mean (SD) | 70.61 (33.02) |
| White cell count, 103 ×, mean (SD) | 7.6 (4.2) |
| Absolute neutrophil count, 103 ×, mean (SD) | 5.8 (3.6) |
| Absolute lymphocyte count, 103 ×, mean (SD) | 1.1 (1.7) |
| Aspartate aminotransferase, IU/L, mean (SD) | 56.85 (49.53) |
| Alanine aminotransferase, IU/L, mean (SD) | 41.6 (51.3) |
| Bilirubin, mg/dl, mean (SD) | 0.65 (0.39) |
| Alkaline phosphatase, IU/L, mean (SD) | 81 (46) |
| C-reactive protein, mg/dl, median (IQR) | 8.3 (3.6–17.3) |
| D-dimer, FEU mg/l, median (IQR) | 1.085 (0.57–2.18) |
| Ferritin, ng/mL, median (IQR) | 613.15 (268.6–1321.7) |
| Procalcitonin, ng/mL, median (IQR) | 0.2 (0.1–0.77) |
| OPN, ng/mL, median (IQR) | 80.42 (43.44–164.0) |
| Outcomes | |
| Need for MV, n (%) | 104 (30.5%) |
| Need for RRT, n (%) | 35 (10.3%) |
| Death, n (%) | 53 (15.5%) |
Abbreviations: BMI: body mass index; eGFR: estimated glomerular filtration rate; IQR: interquartile range; IU: international units; SD: standard deviation; OPN: osteopontin, MV: mechanical ventilation; RRT: renal replacement therapy.